← 返回前沿论文

新型 CD123×CD33 双顺反子嵌合抗原受体 (CAR)-T 疗法可减少单靶点 CAR-T 的逃逸且不增加血液毒性

英文原题:Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single-target CAR-T with no more hematotoxicity.

查看英文原题

Novel CD123×CD33 bicistronic chimeric antigen receptor (CAR)-T therapy has potential to reduce escape from single-target CAR-T with no more hematotoxicity.

PubMed 2023/07/31(内容时间) Cancer Commun (Lond) Q1 · IF 28.4(JCR 2025)

摘要

这条还没有中文摘要(正在补翻译)。 可以先展开下面的英文原文,或点最下面的「在 PubMed 查看」读原文献。

论文信息

作者
Wang Z、Lu Y、Liu Y、Mou J、Liu X、Chen M、Wang Y、Xu Y
单位
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Tianjin Key Laboratory of Cell Therapy for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, P. R. China.China
文献类型
读者来信
期刊
Cancer communications (London, England)2023 Oct
原文标识
PubMed 37525513 · DOI 10.1002/cac2.12474